TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $968,873 | +5.3% | 108,375 | +81.0% | 0.04% | +2.9% |
| Q2 2023 | $919,910 | +75.8% | 59,890 | +157.3% | 0.04% | +59.1% |
| Q1 2023 | $523,387 | +19.5% | 23,272 | +31.0% | 0.02% | -18.5% |
| Q3 2022 | $438,000 | +4.0% | 17,762 | +8.8% | 0.03% | +68.8% |
| Q1 2022 | $421,000 | -43.0% | 16,331 | -31.4% | 0.02% | -51.5% |
| Q4 2021 | $739,000 | +88.5% | 23,800 | +47.3% | 0.03% | +50.0% |
| Q3 2021 | $392,000 | – | 16,154 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |